Results 141 to 150 of about 89,572 (287)

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy

open access: yes, 2017
Haiying Hua,1,* Nan Zhang,2,3,* Dan Liu,1 Lili Song,1 Tuanbing Liu,2,3 Shasha Li,2,3 Yongxing Zhao2,3 1Academy of Medical and Pharmaceutical Sciences, 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, 3Key Laboratory
Song L   +6 more
core  

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma

open access: yes, 2015
Pei-Jian Peng,1,* Bao-Jun Lv,2,* Con Tang,2,* Hai Liao,3 Zhong Lin,1 Yu-Meng Liu,4 Zhi-Hui Wang,1 Si-Yang Wang,5 Zhi-Bin Cheng5 1Department of Medical Oncology, 2Department of Surgical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University ...
Liu YM   +8 more
core  

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

open access: yesCancer Science, EarlyView.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota   +8 more
wiley   +1 more source

Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid

open access: yes, 2011
Chang-Gu Keum1*, Young-Wook Noh1*, Jong-Suep Baek1, Ji-Ho Lim1, Chan-Ju Hwang1, Young-Guk Na1, Sang-Chul Shin2, Cheong-Weon Cho11College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Gungdong, Yuseonggu ...
Hwang CJ   +7 more
core  

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

open access: yesCancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda   +20 more
wiley   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

open access: yes
World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

open access: yesCancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto   +9 more
wiley   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli   +5 more
wiley   +1 more source

Docetaxel induced pericardial effusion

open access: yes, 2007
Docetaxel is a complex diterpene obtained from Taxus Brevifolia, and it is one of the most widely used anticancer agents. The main mechanism of citotoxic action depends on stabilization of microtubules leading to cell mitotic arrest.
Frezza AM   +4 more
core  

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

open access: yesCytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy